90 related articles for article (PubMed ID: 22845411)
1. Hypofractionated radiotherapy in prostate cancer.
Vavassis P; Nguyen DH; Bahary JP; Yassa M
Expert Rev Anticancer Ther; 2012 Jul; 12(7):965-72. PubMed ID: 22845411
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionation for prostate cancer: a critical review.
Miles EF; Lee WR
Semin Radiat Oncol; 2008 Jan; 18(1):41-7. PubMed ID: 18082587
[TBL] [Abstract][Full Text] [Related]
3. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated radiation therapy for prostate cancer: risks and potential benefits in a fiscally conservative health care system.
Aneja S; Pratiwadi RR; Yu JB
Oncology (Williston Park); 2012 Jun; 26(6):512-8. PubMed ID: 22870533
[TBL] [Abstract][Full Text] [Related]
5. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
6. Extreme hypofractionation for prostate cancer.
Lee WR
Expert Rev Anticancer Ther; 2009 Jan; 9(1):61-5. PubMed ID: 19105707
[TBL] [Abstract][Full Text] [Related]
7. Radiobiological rationale and clinical implications of hypofractionated radiation therapy.
Ko EC; Forsythe K; Buckstein M; Kao J; Rosenstein BS
Cancer Radiother; 2011 Jun; 15(3):221-9. PubMed ID: 21514198
[TBL] [Abstract][Full Text] [Related]
8. Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: rationale, technique and early experience.
Koukourakis MI; Touloupidis S; Manavis J; Abatzoglou I; Sismanidou K; Sivridis L
Anticancer Res; 2004; 24(5B):3239-43. PubMed ID: 15510617
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionated radiotherapy for favorable risk prostate cancer.
Rene N; Faria S; Cury F; David M; Duclos M; Shenouda G; Souhami L
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):805-10. PubMed ID: 20510194
[TBL] [Abstract][Full Text] [Related]
10. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer.
Martinez AA; Demanes J; Vargas C; Schour L; Ghilezan M; Gustafson GS
Am J Clin Oncol; 2010 Oct; 33(5):481-8. PubMed ID: 19952715
[TBL] [Abstract][Full Text] [Related]
11. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
Luxton G; Hancock SL; Boyer AL
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of hypofractionated image-guided radiotherapy for localized prostate cancer: outcomes of 55 Gy in 16 fractions at 3.4 Gy per fraction.
Wu JS; Brasher PM; El-Gayed A; Pervez N; Tai PT; Robinson J; Skarsgard D; Joseph K; Sia MA; Pearcey RG
Radiother Oncol; 2012 May; 103(2):210-6. PubMed ID: 22280805
[TBL] [Abstract][Full Text] [Related]
13. Treatment of low-risk prostate cancer with radical hypofractionated accelerated radiotherapy with cytoprotection (HypoARC): an interim analysis of toxicity and efficacy.
Koukourakis MI; Kyrgias G; Papadopoulou A; Panteliadou M; Giatromanolaki A; Sivridis E; Mavropoulou S; Kalogeris K; Nassos P; Milioudis N; Touloupidis S
Anticancer Res; 2011 May; 31(5):1745-51. PubMed ID: 21617234
[TBL] [Abstract][Full Text] [Related]
14. External beam irradiation for localized prostate cancer--the promise of hypofractionation.
Loblaw DA; Cheung P
Can J Urol; 2006 Feb; 13 Suppl 1():62-6. PubMed ID: 16526985
[TBL] [Abstract][Full Text] [Related]
15. Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer.
Leborgne F; Fowler J; Leborgne JH; Mezzera J
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1200-7. PubMed ID: 21477933
[TBL] [Abstract][Full Text] [Related]
16. Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer.
Strigari L; Arcangeli G; Arcangeli S; Benassi M
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1454-60. PubMed ID: 18990503
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity.
Coote JH; Wylie JP; Cowan RA; Logue JP; Swindell R; Livsey JE
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1121-7. PubMed ID: 19131179
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.
Li XA; Wang JZ; Jursinic PA; Lawton CA; Wang D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1251-7. PubMed ID: 15752907
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
